INMUNOTEK at the EAACI 2018 congress

,

INMUNOTEK has been present at the annual conference of the EAACI (European Academy of Allergy and Clinical Immunology). The current edition, EAACI 2018, has taken place in Munich. In addition to the commercial exhibition, INMUNOTEK has participated contributing scientifically in the form of oral communications and posters.

US patent granted

,

The US Patent Office has granted to INMUNOTEK the patent US9901633B2. This refers to new glycoconjugates performed with non-oxidized mannan derived from S. cerevisiae that can be used for designing novel vaccines targeting dendritic cells. This approach is being used for the development of allergy vaccines with improved immunomodulatory properties.

INMUNOTEK has made the 2018 Inc.5000 list

,

Inc. magazine revealed the 2018 Inc. 5000 list of fastest-growing private companies in Europe.  With an accumulated growth of more than 80%, INMUNOTEK has made into this ranking.

Innovation award

,

Inmunotek has been awarded as an Innovative SME (State Confederation of Small and Medium-sized Enterprises) at the Technology and Innovation Awards.

CEPYME500

,

INMUNOTEK has been selected to enter CEPYME500. This is an initiative of CEPYME (State Confederation of Small and Medium-sized Enterprises).

European Academy of Allergy and Clinical Immunology (EAACI)

,

INMUNOTEK has been present at the annual conference of the European Academy of Allergy and Clinical Immunology (EAACI) held in Helsinki.

South Korean delegation visits INMUNOTEK

, ,

On May 29, INMUNOTEK was visited by a South Korean delegation from the Gangneung Science and Industry Promotion Agency (GSIPA).

Congress of SEICAP

,

INMUNOTEK has been present at the Congress of SEICAP (Spanish Society of Clinical Immunology, Allergology and Pediatric Asthma).

INMUNOTEK ranked in Financial Times

,

INMUNOTEK has been ranked in the Financial Times FT 1000. The FT 1000 lists for the first time the 1,000 companies in Europe that have achieved the highest percentage growth.

Agreement with the Complutense University of Madrid

,

INMUNOTEK signs a collaboration agreement with the Complutense University of Madrid for the study of immunomodulators in mesenchymal bone marrow cells.